Abstract
Vindesine 1.75 mg/m2, twice weekly for 2 weeks followed by 2 weeks rest, was given to 26 lung cancer patients. In 6 patients a partial response was seen (23%). Neurotoxicity was present in 15 patients after 1 course; in 6 patients this was the reason for stopping therapy. This regimen has no advantage over weekly vindesine.
Key words: Lung cancer, Vindesine
References
- Mulder NH, Postmus PE, Sleijfer DTh, de Vries EGE, Willemse PHB (1985) Phase one study of twice weekly vindesine. Eur J Cancer Clin Oncol 21:1555–1556 [DOI] [PubMed] [Google Scholar]
- Natale RB, Gralla RJ, Wittes R, Golbey R, Young C (1980) Vindesine chemotherapy in lung cancer. Cancer Treat Rev 7 (Suppl):59–63 [DOI] [PubMed] [Google Scholar]
- Osterlind K, Dombernowsky P, Sorensens PG, Hansen HH (1981) Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma. Cancer Treat Rep 65:245–248 [PubMed] [Google Scholar]
- WHO Handbook for reporting results of cancer treatment WHO offset publication No 48 (1979) The Hague, Nyhoff